Emerging treatments for amyloidosis
Rabya H Sayed1, Philip N Hawkins2, Helen J Lachmann1
11] National Amyloidosis Centre, UCL Medical School, Royal Free Hospital, London, UK [2] UCL Centre for Nephrology, UCL Medical School, Royal Free Hospital, London, UK.
New targeted therapies are emerging for amyloidosis, a disease caused by protein misfolding that can lead to organ failure. These novel treatments, including protein stabilizers and immunotherapy, are now in clinical trials.
Area of Science:
- Biochemistry
- Pathology
- Pharmacology
Background:
- Amyloidosis is a group of diseases characterized by protein misfolding and subsequent amyloid deposition.
- These conditions often lead to organ failure and have historically had limited treatment options and poor prognoses.
Purpose of the Study:
- To review emerging targeted therapeutic approaches for amyloidosis.
- To highlight treatments currently under investigation in clinical trials.
Main Methods:
- Review of current scientific literature and clinical trial data.
- Categorization of emerging therapies based on their mechanism of action.
Main Results:
- Identification of several novel therapeutic strategies including protein stabilizers, fibrillogenesis inhibitors, fibril disruptors, and immunotherapy.
- Confirmation that these approaches are actively being assessed in clinical trials.
Conclusions:
- Targeted therapies represent a significant advancement in the treatment of amyloidosis.
- Ongoing clinical trials are evaluating the efficacy and safety of these novel approaches, offering new hope for patients.
More Related Videos
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
06:17A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
Related Concept Videos
Alzheimer's Disease: Treatment
Targeted Cancer Therapies
There are several types of targeted therapies against...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
